Biogen Inc BIIB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/26/22 EDT
195.75UNCH (UNCH)
Volume
32,277
Close
195.75quote price arrow down-2.03 (-1.03%)
Volume
989,009
52 week range
187.16 - 291.54
Loading...
  • Open197.44
  • Day High199.80
  • Day Low194.63
  • Prev Close195.75
  • 52 Week High291.54
  • 52 Week High Date09/28/21
  • 52 Week Low187.16
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap28.668B
  • Shares Out146.45M
  • 10 Day Average Volume1.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.40
  • YTD % Change-18.41

KEY STATS

  • Open197.44
  • Day High199.80
  • Day Low194.63
  • Prev Close195.75
  • 52 Week High291.54
  • 52 Week High Date09/28/21
  • 52 Week Low187.16
  • 52 Week Low Date05/09/22
  • Market Cap28.668B
  • Shares Out146.45M
  • 10 Day Average Volume1.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.40
  • YTD % Change-18.41

RATIOS/PROFITABILITY

  • EPS (TTM)14.01
  • P/E (TTM)13.98
  • Fwd P/E (NTM)12.41
  • EBITDA (TTM)3.397B
  • ROE (TTM)18.20%
  • Revenue (TTM)10.634B
  • Gross Margin (TTM)77.34%
  • Net Margin (TTM)14.61%
  • Debt To Equity (MRQ)61.29%

EVENTS

  • Earnings Date10/18/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Related Video

Tuesday, Sept. 6, 2022: The Club is adding more shares of this beaten-up tech name
VIDEO11:3811:38
CNBC Investing ClubTuesday, Sept. 6, 2022: The Club adds more shares of this beaten-up tech name

Profile

MORE
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board
Michel Vounatsos
Chief Executive Officer, Director
Michael McDonnell
Chief Financial Officer, Executive Vice President
Alphonse Galdes Ph.D.
Executive Vice President, Pharmaceutical Operations and Technology
Rachid Izzar
Executive Vice President, Head of Alzheimers Disease and Dementia Business Unit
Address
225 Binney Street
Cambridge, MA
02142
United States

Top Peers

SYMBOLLASTCHG%CHG
ILMN
Illumina Inc
184.12-6.26-3.29%
ALNY
Alnylam Pharmaceuticals Inc
197.39-3.39-1.69%
BNTX
BioNTech SE
127.65-0.70-0.55%
GMAB
Genmab A/S
31.52-0.31-0.97%
INCY
Incyte Corp
66.18-0.71-1.06%